Cambridge Nutritional Sciences plc (CNSL)
Dec 27, 2024 - CNSL was delisted (reason: acquired by Searchlight and BCI)
4.720
0.00 (0.00%)
Inactive · Last trade price on Dec 26, 2024
CNSL Employees
Cambridge Nutritional Sciences had 94 employees as of March 31, 2024. The number of employees increased by 3 or 3.30% compared to the previous year.
Employees
94
Change (1Y)
3
Growth (1Y)
3.30%
Revenue / Employee
$127,956
Profits / Employee
$2,481
Market Cap
11.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 94 | 3 | 3.30% |
| Mar 31, 2023 | 91 | 6 | 7.06% |
| Mar 31, 2022 | 85 | -86 | -50.29% |
| Mar 31, 2021 | 171 | 19 | 12.50% |
| Mar 31, 2020 | 152 | 0 | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
CNSL News
- 3 months ago - Consolidated Communications Closes Inaugural $1.344 Billion Asset Backed Securitization and $1.5 Billion Revolving Warehouse Facility - Business Wire
- 3 months ago - KBRA Assigns Preliminary Ratings to Consolidated Communications, LLC and Fidium Fiber Finance Holdco LLC, Series 2025-1, 2025-2 and 2025-3 Secured Notes - Business Wire
- 6 months ago - Consolidated Communications Announces Availability of Certain Financial Information - Business Wire
- 10 months ago - Consolidated Communications Announces Third Quarter 2024 Financial Results - Business Wire
- 10 months ago - Consolidated Communications to Release Third Quarter 2024 Earnings on Nov. 5 - Business Wire
- 11 months ago - Consolidated Communications Awards $50,000 to Schools in 2024 to Support Technology Use in Education - Business Wire
- 1 year ago - Consolidated Communications Announces Second Quarter 2024 Financial Results - Business Wire
- 1 year ago - Tris Pharma Presents New Clinical Data Demonstrating Robust Safety and Efficacy of Investigational, First-in-Class Therapy Cebranopadol for Treatment of Pain - Business Wire